The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: A decision analysis

Cancer

Volumn 106, Issue 12, 2006, Pages 2576-2582

  Punglia, Rinaa S ^a   Kuntz, Karen M ^b   Winer, Eric P ^a,c   Weeks, Jane C ^a,c   Burstein, Harold J ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Aromatase inhibitor; Breast cancer; Decision analysis; Post menopausal; Progesterone receptor; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; PROGESTERONE RECEPTOR; TAMOXIFEN CITRATE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; ENZYME INHIBITION; FEMALE; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CROSS-OVER STUDIES; DECISION SUPPORT TECHNIQUES; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MARKOV CHAINS; MIDDLE AGED; MODELS, STATISTICAL; MODELS, THEORETICAL; NEOPLASM STAGING; ODDS RATIO; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, PROGESTERONE; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 33745195504     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21919     Document Type: Article

References (16)

1. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998;351:1451-1467.
2. Punglia RS, Kuntz KM, Winer EP, et al. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol. 2005; 23:5178-5187.
3. Howell A on behalf of the ATAC Trialists' Group. The ATAC ('Arimidex,' Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer-updated efficacy results based on a median follow-up of 5 years [abstract 1]. Breast Cancer Res Treat. 2004;88(Suppl 1);S7.
4. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366:455-462.
5. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13: 322-338.
6. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet. 2002;359:2131-2139.
7. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003;98:1802-1810.
8. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21:1973-1979.
9. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in post-menopausal women with early breast cancer. N Engl J Med. 2005;353:2747-2757.
10. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793-1802.
11. Coombes RC, Hall E, Gibson, LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081-1092.
12. Boccardo F, Rubagotti A, Puntoni M, et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. J Clin Oncol. 2005;23: 5138-5147.
13. Thurlimann BJ, Keshaviah A, Mouridsen H, et al. BIG 1-98: randomized double-blind Phase III study to evaluate letrozole vs. tamoxifen for postmenopausal women with receptor-positive breast cancer [abstract 511]. Proc Am Soc Clin Oncol. 2005;23(Suppl 1):6S.
14. Cuzick J, Howell A. Optimal timing of an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone receptor-positive breast cancer [abstract 658]. J Clin Oncol. 2005;23(16S):43s.
15. Elledge RM, Allred DC. Clinical aspects of estrogen and progesterone receptors. In: Harris JH, Lippman ME, Morrow M, Osborne CK, editor. Diseases of the Breast. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2004:603-617.
16. Cui XJ, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005;23:7721-7735.